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Nicotinic acetylcholine (ACh) receptors (nAChRs) are included among the targets of
a variety of local anesthetics, although the molecular mechanisms of blockade are
still poorly understood. Some local anesthetics, such as lidocaine, act on nAChRs
by different means through their ability to present as both charged and uncharged
molecules. Thus, we explored the mechanisms of nAChR blockade by tetracaine, which
at physiological pH is almost exclusively present as a positively charged local anesthetic.
The nAChRs from Torpedo electroplaques were transplanted to Xenopus oocytes
and the currents elicited by ACh (IAChs), either alone or co-applied with tetracaine,
were recorded. Tetracaine reversibly blocked IACh, with an IC50 (i.e., the concentration
required to inhibit half the maximum IACh) in the submicromolar range. Notably, at very
low concentrations (0.1µM), tetracaine reduced IACh in a voltage-dependent manner,
the more negative potentials produced greater inhibition, indicating open-channel
blockade. When the tetracaine concentration was increased to 0.7µM or above,
voltage-independent inhibition was also observed, indicating closed-channel blockade.
The IACh inhibition by pre-application of just 0.7µM tetracaine before superfusion of ACh
also corroborated the notion of tetracaine blockade of resting nAChRs. Furthermore,
tetracaine markedly increased nAChR desensitization, mainly at concentrations equal
or higher than 0.5µM. Interestingly, tetracaine did not modify desensitization when
its binding within the channel pore was prevented by holding the membrane at
positive potentials. Tetracaine-nAChR interactions were assessed by virtual docking
assays, using nAChR models in the closed and open states. These assays revealed
that tetracaine binds at different sites of the nAChR located at the extracellular and
transmembrane domains, in both open and closed conformations. Extracellular binding
sites seem to be associated with closed-channel blockade; whereas two sites within
the pore, with different affinities for tetracaine, contribute to open-channel blockade
and the enhancement of desensitization, respectively. These results demonstrate a
concentration-dependent heterogeneity of tetracaine actions on nAChRs, and contribute
to a better understanding of the complex modulation of muscle-type nAChRs by local
anesthetics. Furthermore, the combination of functional and virtual assays to decipher
nAChR-tetracaine interactions has allowed us to tentatively assign the main nAChR
residues involved in these modulating actions.
Keywords: tetracaine, nicotinic acetylcholine receptors, Xenopus oocytes, microtransplanted receptors,
desensitization, mechanisms of blockade
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INTRODUCTION
The muscle-type nicotinic acetylcholine (ACh) receptor
(nAChR) is the prototypical member of the Cys-loop family of
ligand-gated ion channels. This receptor is a heteropentameric
protein that is highly expressed by muscle fibers at the
neuromuscular junction, and it is composed of 2α1, β1, δ, and
ε (substituted by γ during fetal life or in denervated fibers)
subunits that are arranged to form a central channel pore
(Albuquerque et al., 2009). From a functional point of view,
nAChRs are key elements for striated-muscle activation by
motoneurons, and thus, for executing voluntary movements.
The nAChRs are also expressed in both the central and
peripheral nervous systems, and even in non-neuronal tissues,
such as astrocytes, keratinocytes, lymphoid cells, lung epithelial
cells, and vascular smooth muscle and endothelial cells (Gotti
and Clementi, 2004). Although all nAChRs share many
structural properties, neuronal nAChRs differ from their
muscle-type counterparts in the large diversity of their subunit
compositions, which in some cases are tissue specific, and
in the associated heterogeneity of their physiological and
pharmacological properties (Albuquerque et al., 2009; Taly et al.,
2009). Remarkably, these receptors constitute a key therapeutic
target, given the high prevalence and relevance of disorders
related to nAChR dysfunction, including some myasthenias,
addictive behaviors, some types of epilepsy, schizophrenia,
Parkinson’s and Alzheimer’s diseases, inflammation, pain,
and even cancer (Hurst et al., 2013; Wu et al., 2015; Parikh
et al., 2016; Schulte et al., 2016). Therefore, over the last few
decades, much effort has been devoted to understand the
mechanisms underlying nAChR modulation, as a large number
of highly different molecules affect their functional properties,
enabling these receptors to act as allosteric proteins (Changeux,
2014).
Local anesthetics (LAs) are listed among the molecules known
to inhibit nAChR activity, including some that are widely used
in clinical practice, such as lidocaine (Steinbach, 1968; Wang
et al., 2010; Alberola-Die et al., 2011), procaine (Katz and
Miledi, 1975; Adams, 1977; Gage and Wachtel, 1984), tetracaine
(Ttc) (Koblin and Lester, 1979; Gallagher and Cohen, 1999;
Gentry and Lukas, 2001), bupivacaine (Ikeda et al., 1984),
benzocaine (Koblin and Lester, 1979; Ogden et al., 1981),
adiphenine, and proadifen (Gentry and Lukas, 2001; Spitzmaul
et al., 2009). Most LAs seem to be able to inhibit nAChRs;
however, there are marked differences among their molecular
structures and potencies for nAChR blockade, suggesting that
they might not bind to the same modulating sites on these
receptors, which would explain their heterogeneous actions on
nAChRs. Notably, we have found that lidocaine exerts multiple
inhibitory actions on muscle- and neuronal-type nAChRs
Abbreviations: ACh, acetylcholine; ANR, normal Ringer solution with atropine;
DEA, diethylamine; DMA, 2,6-dimethylaniline; EC, extracellular; IACh, ACh-
elicited current; IC, intracellular; Ip, IACh amplitude at the peak; Iss, IACh
amplitude at the steady-state; LA, local anesthetic; MS-222, ethyl 3-aminobenzoate
methanesulfonate; n, number of oocytes; N, number of oocyte-donor frogs;
nAChR, nicotinic acetylcholine receptor; NR, normal Ringer solution; TM,
transmembrane spanning-segment; Ttc, tetracaine.
(Alberola-Die et al., 2011, 2013). Furthermore, most actions of
lidocaine on the muscle-type nAChR can be ascertained by using
structural analogs of either its hydrophilic (diethylamine; DEA)
or hydrophobic (dimethylaniline; DMA) moieties (Alberola-
Die et al., 2016a,b). The polar, charged DEA is responsible for
the voltage-dependent blockade of nAChRs. DEA also elicits
closed-channel blockade, mainly through its action on residues
at the extracellular domain (ECD) (Alberola-Die et al., 2016a).
In contrast, nAChR blockade by the uncharged, hydrophobic
DMA is voltage-independent (although it can bind to the
open-channel pore), and it mainly occurs through interactions
outside the pore both at the ECD and, preferentially, at
inter-subunit crevices on the transmembrane-spanning domain
(TMD) to elicit closed-channel blockade. Moreover, DMA
enhances nAChR desensitization (Alberola-Die et al., 2016b).
As a long-lasting amino-ester anesthetic, Ttc (2-
(dimethylamino)ethyl 4-(butylamino)benzoate) is widely
used in topical preparations, as well as spinal anesthesia and
plexus/major nerve blocks, especially when a long duration
of anesthesia is required. Similar to lidocaine, Ttc belongs to
the group of LAs (Arias, 1999) that possess a single aromatic
ring (see Figure 1A). However, it also has an ester group
that is linked to an aliphatic chain that ends in a tertiary
amine, which at pH 7, is largely protonated. Besides blocking
voltage-dependent Na+ channels, Ttc has inhibitory effects on
muscle (Gallagher and Cohen, 1999; Middleton et al., 1999)
and neuronal nAChRs (Gentry and Lukas, 2001), as well as
on high-voltage-activated calcium channels (Sugiyama and
Muteki, 1994), ryanodine receptors (Zucchi and Ronca-Testoni,
1997), and acid-sensing ion channels (ASICs) (Leng et al.,
2013). However, the mechanisms underlying the effects of Ttc
on nAChRs remain largely unknown. Since some LAs with
amine groups act on nAChRs by different mechanisms and
the heterogeneity of their actions are, at least partially, related
to the equilibrium between charged and uncharged forms, we
have now explored the mechanisms of nAChR blockade by Ttc.
Considering its pKa of 8.4 (Chemicalize, https://chemicalize.
com/), almost 97% of Ttc molecules are in a charged form
at the recording pH (pH = 7.0). Notably, we found that Ttc
induced a much stronger blockade of muscle-type nAChRs than
either lidocaine or its charged hydrophilic moiety, DEA. We
have now discovered that a roughly homogeneous pool of Ttc
molecules elicit both open- and closed-channel blockade and
markedly increase nAChR desensitization. These heterogeneous
effects of Ttc on nAChRs are mediated by its interaction with
different nAChR residues, located at both the ECD and the
TMD.
Preliminary results have been published elsewhere in an
abstract form (Cobo et al., 2014).
MATERIALS AND METHODS
Purification and Reconstitution of nAChRs
The nAChRs from Torpedo marmorata electroplaques were
purified by bromoacetylcholine-affinity chromatography in the
presence of asolectin lipids, using cholate as a detergent.
After elution with carbamylcholine, purified receptors were
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FIGURE 1 | Tetracaine (Ttc) inhibition of currents elicited by ACh (IAChs).
(A) Molecular structure of Ttc, showing the amine group largely charged at the
recording pH. (B) Superimposed IAChs elicited by 10µM ACh either alone
(Control) or co-applied with different Ttc concentrations, as stated on the right.
Note that IAChdecay was accelerated at Ttc concentrations of 0.5µM or
higher. Unless otherwise stated, the holding potential was −60mV, downward
deflections represent inward currents and the bars above the recordings
indicate the timing of drug application. (C) Ttc concentration-IACh inhibition
relationship. Peak (Ip; black symbols) and steady state (Iss, measured 20 s
after the peak; gray symbols) IACh amplitudes elicited in the presence of Ttc
were normalized to the IACh evoked by ACh alone (Control) and represented
against the logarithm of Ttc concentration. Solid and dashed lines are sigmoid
curves fitted to Ip and Iss data, respectively. Note that both curves overlap up
to 0.1µM Ttc. Error bars indicate SEM. Each point is the average of 4–23
oocytes from 3 to 11 frogs.
dialyzed and reconstituted in asolectin lipids at a final protein
concentration of 0.3–1.2 mg/mL. Samples were aliquoted and
stored in liquid nitrogen (Ivorra et al., 2002).
Oocyte Preparation and Microinjection
Adult female Xenopus laevis (purchased from Harlan Interfauna
Ibérica S.L., Barcelona, Spain; and Centre National de la
Recherche Scientifique, Montpellier, France) were immersed
in cold 0.17% tricaine methanesulfonate (MS-222) for 20min,
and a piece of the ovary was drawn out aseptically. Animal
handling was carried out in accordance with the guidelines
for the care and use of experimental animals adopted by the
European Union, and the animal protocol was approved by
the Ethics Committee of Universidad de Alicante. Stage V
and VI oocytes were isolated and their surrounding layers
were removed manually. Cells were kept at 15–16◦C in a
modified Barth’s solution (88mM NaCl, 1mM KCl, 2.40mM
NaHCO3, 0.33mM Ca(NO3)2, 0.41mM CaCl2, 0.82mM
MgSO4, 10mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-
1-sulfonic acid (HEPES; pH 7.4), 100 U/mL penicillin, and
0.1 mg/mL streptomycin) until further use. Oocytes were
microinjected with 100 nL of an aliquot of reconstituted nAChRs
(Morales et al., 1995).
Two-Electrode Voltage-Clamp Recordings
in Oocytes
Membrane current recordings were performed at 21–25◦C, 16–
72 h after injection of proteoliposomes, using a high-compliance
two-microelectrode voltage-clamp system (TurboTEC-10CD,
npi Tamm, Germany). The recording methodology has been
previously described (Morales et al., 1995; Alberola-Die et al.,
2016b). Briefly, oocytes were placed in a 150-µL recording
chamber and continuously superfused with normal frog Ringer’s
solution (NR: 115mM NaCl, 2mM KCl, 1.8mM CaCl2, 5mM
HEPES, pH 7.0) supplemented with 0.5µM atropine sulfate
(normal Ringer with atropine, ANR) to block any muscarinic
response (Kusano et al., 1982). The membrane potential was
held at −60mV, unless otherwise specified. Oocytes were
superfused with ACh and the other drugs under investigation
that had been diluted in ANR solution. Superfusion of the
oocytes was conducted at a flow rate of 13–17 mL/min.
Membrane currents elicited by ACh (IACh), either alone or
co-applied with Ttc, were low-pass filtered at 30–1,000Hz,
after sampling at fivefold the filter frequency (Digidata series
1550 and 1440A; Axon Instruments, Foster City, CA, USA),
as recorded on two PC-computers using the WCP v. 4.8.6.
package developed by J. Dempster (Strathclyde Electrophysiology
Software, University of Strathclyde, Scotland, UK) and AxoScope
v. 10.0.0.60 software (Molecular Devices Corporation, Sunnyvale,
CA, USA).
Experimental Design
Experimental procedures were similar to those used to study
the effects of lidocaine (Alberola-Die et al., 2011) and other
modulators (Alberola-Die et al., 2016a,b) on nAChRs. Briefly, the
Ttc concentration-IACh inhibition relationship was determined
bymeasuring IAChs evoked by 10µMACh alone, or together with
different concentrations of Ttc. For the competition assays, ACh
concentration-IACh amplitude curves were obtained by bathing
injected oocytes with increasing concentrations of ACh, either
alone or together with 0.7µM Ttc. The IAChs were normalized
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 August 2018 | Volume 11 | Article 193
Cobo et al. Mechanisms of nAChR Inhibition by Tetracaine
to the maximum IACh evoked by ACh alone, and the values
were fitted to a sigmoid curve (see Equation 3 below). To allow
nAChRs to recover from desensitization, the interval between
consecutive ACh applications was at least 5min. To assess the
blockade of resting nAChRs by Ttc, we compared the IAChs
elicited by ACh (from 1µM to 1mM) alone, or co-applied with
0.7µM Ttc, either directly, or after 12 s of Ttc pre-application (at
the same concentration). To better characterize the effects of Ttc
on nAChR desensitization and compare IACh deactivation in the
presence and the absence of Ttc, in some experiments, the oocyte
remained superfused with Ttc (at 0.1 or 0.7µM) for 12 s after
withdrawal of 100µMACh.
Voltage dependence of the IACh blockade by Ttc was assessed
by: (i) applying a series of 800ms voltage pulses (from −120 to
+60mV, in 20mV steps) to the oocyte before ligand superfusion
and during the IACh plateau elicited by 10µM ACh, either alone,
or co-applied with different concentrations of Ttc; the −120mV
pulse duration was extended up to 1500ms to allow a more
complete current relaxation. (ii) From a holding potential of
−60mV, applying a single 800ms voltage pulse to either +40 or
+60mV during the IACh plateau elicited by 10µM ACh, either
alone, or when co-applied with 0.1 or 0.7µMTtc. (iii) Comparing
the IACh blockade induced by co-application of 0.7µM Ttc with
10µM ACh, to the effect when 0.7µM Ttc was just pre-applied
or administered with a combined pre- and co-application, while
holding the membrane potential either at−60 or+40mV.
Data Analysis and Statistical Procedures
Inhibition curves were determined by measuring the IACh evoked
by 10µM ACh in the presence of different concentrations of
Ttc. The IAChs (both at the peak and 20 s after) elicited in the
presence of Ttc were normalized to the IACh evoked by ACh
alone. Data were fitted to a logistic curve with the Origin 6.1
software (OriginLab Corp. Northampton, MA, U.S.A.), using the
following Equation (1):
IACh+Ttc =
(
IAChmax − IAChmin
1+ ([Ttc] /IC50)nH
)
+ IAChmin
where IACh+Ttc is the IACh amplitude elicited by co-application of
10µM ACh with Ttc at a given concentration ([Ttc]); IAChmax
and IAChmin are the maximum and minimum IAChs recorded,
respectively; IC50 is the Ttc concentration required to inhibit half
the maximum IACh; and nH is the Hill coefficient.
The rate of desensitization was determined from the IACh
decay elicited by ACh (10 or 100µM), either alone, or co-
applied with different concentrations of Ttc (0.1–2µM). The
time constant of the IACh decay was obtained through fitting
to an exponential decay curve using the OriginPro 8 software
(OriginLab Corp. Northampton, MA, U.S.A.). In addition, based
on the methods of Sobolevsky et al. (1999), the change in the rate
of desensitization induced by Ttc (0.01–2µM) was determined
using the following Equation (2):
IACh desensitization change =
(
Iss_Ttc/Ip_Ttc
Iss_Ctr/Ip_Ctr
)
where Ip_Ctr and Ip_Ttc are the IACh peaks elicited by ACh (10
or 100µM) either alone, or together with Ttc, respectively;
Iss_Ctr and Iss_Ttc are IAChs 20 s after the corresponding IACh
peaks.
To characterize the pharmacological profile of Ttc, nAChRs
were activated by different concentrations of ACh alone, or co-
applied with Ttc, at roughly its IC50, either directly, or after its
pre-application for 12 s. Dose-response data were fitted to the
following form of the Hill Equation (3):
I
IAChmax
=
[
1+
(
EC50[
ACh
]
)nH]−1
where I is the IACh amplitude elicited at a given concentration
of ACh ([ACh]) applied either alone, or together with Ttc;
EC50 is the agonist concentration required to obtain one-
half the maximum IACh; and IAChmax and nH are as in
Equation (1).
Net i/v curves for IACh were obtained by subtracting,
for each voltage, the steady state currents attained in ANR
(measured during the last 100ms of the pulse) from the
corresponding currents recorded in the presence of 10µM
ACh alone, or together with Ttc. These net IACh values
were normalized, for each oocyte, to the ACh response
at−60mV.
Unless otherwise specified, values presented were the mean
± standard error of the mean (SEM); “n” indicates the number
of oocytes and “N” is the number of oocyte-donor frogs
from which the data were obtained. When comparing two-
group means of normally distributed values, the Student’s t-
test was used; otherwise, the Mann–Whitney rank-sum test
was applied. Among-group differences were determined by the
analysis of variance (ANOVA), and mean differences for each
pair of groups were determined with the Bonferroni t-test.
The one-sample t-test was used to compare the mean of an
experimental group with a specified value. For the comparison
of EC50 and IC50 values, we used the confidence intervals (CIs)
computed by the curve-fitting function of the Origin 6.1 software,
using 95% confidence levels. The criterion of “non-overlapping
95% confidence intervals” was used to determine significant
differences. A significance level of p< 0.05 was considered in all
cases.
Virtual Docking Assays
Docking assays were carried out as previously described
(Alberola-Die et al., 2016a,b). Briefly, Torpedo nAChR structures
in the closed (4 Å resolution, pdb code 2BG9; Unwin, 2005) and
open (6.2 Å resolution, pdb code 4AQ9; Unwin, 1995; Unwin and
Fujiyoshi, 2012), were obtained from the Research Collaboratory
for Structural Bioinformatics (RCSB) Protein Data Bank (PDB).
The specific edition of the protein was made using DeepView
v4.1 (Guex and Peitsch, 1997) and Yasara (Krieger et al., 2002,
2004) software without further optimization. The structure of
Ttc was obtained from the National Center for Biotechnology
Information (NCBI) PubChem database (http://www.ncbi.
nlm.nih.gov/pccompound). A global docking procedure
was accomplished with AutoDock 4 (Morris et al., 2008)
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implemented in Yasara, in which a total of 800 flexible docking
runs were set and clustered around the putative binding sites. The
program then performed a simulated annealing minimization
of the complexes, which moved the structure to a nearby
stable energy minimum, by using the implemented (Assisted
Model Building with Energy Refinement) AMBER 99 force field
(Duan et al., 2003). The Yasara pH command was set to 7.0, to
ensure that molecules preserved their pH dependency of bond
orders and protonation patterns. In this way, 97% of the Ttc
molecules were protonated. The best binding energy complex
in each cluster was stored, analyzed, and used to select the best
orientation of the interacting partners.
Global docking of Ttc on the nAChR channel pore
systematically occurred at a single, high-affinity binding site.
Thus, no other sites were found, following this strategy. In order
to explore alternative binding sites with lower affinities within the
pore, the high-affinity site was blocked with a Ttc molecule before
starting subsequent docking runs. We used the best position of
Ttc bound to the deep residues within the pore. In this way,
we ensured that the high-affinity site was already occupied, and
simulated a scenario with a high concentration of Ttc. Figures
were drawn with open source PyMol (The PyMOL Molecular
Graphics System, Version 1.8 Schrödinger, LLC, at http://www.
pymol.org/).
The theoretical affinities of Ttc at its binding site can be
determined by calculating the binding energy of the ligand-
receptor complex. The binding energy is obtained by measuring
the energy at infinite distance (the unbound state) and
subtracting from that value the energy of the complex (the bound
state). The relationship between the Gibbs free energy of binding
(1G, cal/mol) and the dissociation constant (Kd) was determined
by the following Equation (4):
1G = − RT lnKd
where R= 1.98 cal/molK and T = 298K. Thus, the more positive
the binding energy, the more favorable the interaction in the
context of the chosen force field.
Drugs
The drugs ACh, atropine sulfate, Ttc, MS-222, penicillin, and
streptomycin were obtained from Sigma (St. Louis, MO, USA),
and HEPES was obtained from Acros Organics (New Jersey, NJ,
USA). The reagents of general use were purchased from Scharlau
Chemie SA (Barcelona, Spain). All solutions were made in ANR
just before each application.
RESULTS
Inhibition of IACh by Ttc
The superfusion of Ttc (see chemical structure in Figure 1A)
on either uninjected oocytes or those bearing nAChRs, with
the membrane potential clamped at −60mV, did not modify
their cell membrane conductance, even at concentrations as
high as 1mM. In contrast, co-application of 10µM ACh
with 1 nM−100µM Ttc reversibly inhibited IACh, in a dose-
dependent manner (Figure 1B). The IC50 and nH values (see
Equation 1) for the IACh peak (Ip) were 0.7µM (95% CI, 0.5–
0.9µM; n = 4–23, N = 3–11) and 0.7 ± 0.1, respectively
(black circles and continuous line; Figure 1C). At low Ttc
concentrations (up to 0.1µM), this Ip inhibition was similar to
that measured 20 s after Ip, which will be referred to hereafter as
the “steady state current” (Iss). However, at Ttc concentrations
higher than 0.1µM, the Iss blockade was significantly greater
than the corresponding Ip inhibition (see Figure 1B). Thus, the
dose-inhibition curve for the Iss showed an IC50 of 0.3µM
(95% CI, 0.2–0.4µM, same cells and donor frogs as above)
and a slope of 1.0 ± 0.1 (gray circles and dashed line;
Figure 1C). Interestingly, the effects of Ttc on muscle-type
nAChR was specific, as gamma-aminobutyric acid (GABAA)
receptors (GABAARs), which also belong to the Cys-loop
family of receptors, were not noticeably affected by Ttc, even
at concentrations of 100-fold the IC50 of Ttc on IACh (see
Figure S1).
Voltage Dependence of nAChR Blockade
by Ttc
To elucidate whether IACh inhibition by Ttc is voltage-dependent,
voltage pulses were applied to oocytes while superfusing them
with ANR, or during the IACh plateau elicited by 10µM ACh,
either alone, or together with 0.1 or 0.7µMTtc (Figures 2A1,A2,
respectively; see Experimental design in Material and methods).
The i/v curves of net IAChs elicited by ACh, either alone, or
co-applied with 0.1 or 0.7µM Ttc, showed that neither IACh
reversal potential, close to 0mV, nor its inward rectification
were affected by the presence of Ttc (Figures 2B1,B2; see
also Morales et al., 1995). However, co-application of 10µM
ACh with 0.1µM Ttc reduced IACh amplitude in a voltage-
dependentmanner; thus, themore hyperpolarized themembrane
potential, the larger the blockade (Figure 2B1). This suggests
that Ttc, at this concentration, mainly binds within the channel
pore.
An additional mechanism of blockade was present when
0.7µM Ttc was co-applied with ACh, which roughly accounted
for 35% of IACh inhibition at positive potentials (Figure 2B2).
It ought to be considered that positive potentials should eject
the positively charged Ttc from the channel pore. Therefore,
this added IACh inhibition seems voltage-independent, indicating
that at concentrations close to the IC50, Ttc also interacts with
nAChR residues located outside the pore. Nonetheless, the
voltage-dependent blockade of IACh remained at 0.7µM Ttc
(compare the extent of IACh blockade at negative versus positive
potentials in Figure 2B2; see also Figure S2, which plots the
IACh remnant vs. membrane potential when ACh was co-applied
with different concentrations of Ttc). This voltage-dependent
inhibition facilitates the estimation of the apparent rate of
channel pore blockade. Thus, during the IACh plateau elicited by
10µM ACh in the presence of 0.1 or 0.7µM Ttc, the membrane
potential was stepped back to −60mV, after an 800ms pulse at
either +40 or +60mV, (Figure 2C1). As shown in Figure 2C2,
IACh blockade at −60mV followed an exponential function with
time constant values of 749 ± 32ms (n = 10, N = 3) and 332
± 25ms (n = 11; N = 4) for 0.1 and 0.7µM Ttc, respectively.
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FIGURE 2 | Voltage dependence of nicotinic acetylcholine receptor (nAChR) blockade by tetracaine (Ttc). (A) IAChs (upper traces) elicited by 10µM ACh either alone
(A1,A2, black recordings), or in the presence of 0.1µM (A1, orange), or 0.7µM Ttc (A2, red) when the voltage protocol, indicated below the currents, was applied.
(B) Plots of net i/v relationships for IAChs evoked, following the protocol shown in A. Control IAChs are represented by black symbols and lines (B1,B2), whereas those
(Continued)
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FIGURE 2 | evoked in the presence of 0.1µM (B1) and 0.7µM Ttc (B2) are drawn in orange and red, respectively. Values were normalized as a percentage of current
with reference to their control IACh at −60mV. Each point is the average of 5 (N = 1) and 12 (N = 3) cells for 0.1 and 0.7µM Ttc, respectively. (C) Kinetics of the
voltage-dependent blockade of nAChRs at −60mV. (C1) IAChs were elicited by 10µM ACh alone (control, black recordings), or together with either 0.1µM (orange
trace) or 0.7µM Ttc (red recording) at −60mV; during the IACh plateau, an 800ms voltage jump to +40mV was given (bottom trace shows the voltage protocol).
Membrane leak currents (recorded in the absence of ACh) have been subtracted. (C2) Zoomed in view of the areas indicated by arrows in C1 (immediately after the
voltage jump). Kinetics of the voltage-dependent blockade of nAChRs by 0.1µM (orange trace) and 0.7µM Ttc (red trace) were determined by fitting the net IACh
decays to exponential functions (green curves over the recordings). The small, slow IACh changes evoked by the voltage pulse when the cell was bathed solely with
ACh (black recordings in C1) have been subtracted. (C3) Time constant values of the voltage-dependent IACh blockade kinetics elicited by 0.1 and 0.7µM Ttc.
Asterisk indicates significant differences between both values (p < 0.05, t-test).
Thus, the kinetics of the voltage-dependent blockade of IACh were
accelerated with increasing Ttc concentration (p < 0.05, t-test;
Figure 2C3).
Pharmacological Profile of IACh Blockade
by Ttc
To better characterize the mechanisms underlying IACh
inhibition by Ttc, oocytes were superfused with ACh at different
concentrations (1, 3, 10, 100µM, and 1mM) alone, or co-applied
with 0.7µM Ttc, either directly, or after a 12 s pre-application of
the same Ttc concentration (Figure 3A1,A2, respectively). When
ACh and Ttc were directly co-applied, the IACh amplitude was
reduced roughly by half (as would be expected from the estimated
IC50 of Ttc), independently of the ACh dose tested (see records
in Figures 3A1,B,C). This indicates that Ttc was acting by a non-
competitive mechanism of inhibition. The estimated EC50 values
of the ACh dose-IACh amplitude curves obtained when Ttc was
either co-applied, or pre- and co-applied with ACh, were similar
to those observed in control curves, in which ACh was applied
alone. In particular, the EC50 values were 37µM for the control
curve (95% CI 32–43µM; n= 10–13, N = 3) vs. 49µM (95% CI
42–55µM; n= 3–6, N = 2) and 21µM (95% CI 12–36; n= 4–7,
N = 2) for the sole Ttc and ACh co-application, and the Ttc pre-
and co-application, respectively (p > 0.05). The IACh blockade
elicited by pre- and co-application of Ttc was also independent
of the ACh dose (56–75% at different concentrations). However,
the extent of IACh inhibition was significantly greater than
that observed with ACh and Ttc co-application alone (48–
55%, p < 0.05 ANOVA; Figure 3C), unless at very low ACh
concentrations (3µM). Since the probability of unliganded
nAChRs being open is less than one in a million (Nayak et al.,
2012), it turns out that the increased nAChR blockade by Ttc
pre-application, before its co-application with ACh, is due to
Ttc binding to resting (closed) nAChRs. Consequently, Ttc pre-
application would block nAChRs before they can be gated by the
agonist.
Differential Effects of Ttc on IACh
Depending on Membrane Potential and
Application Time
As mentioned above, nAChR inhibition by Ttc at relatively high
concentrations (IC50 or above) involved both open- and closed-
channel blockade. To better understand the effects of Ttc on
nAChRs at these concentrations, oocytes were clamped at two
different potentials (−60 or +40mV), and IAChs were elicited by
32 s superfusion of 10µM ACh either alone (Figures 4A1-A6,
black recordings), or with 0.7µM Ttc (Figures 4A1-A6, red
recordings) in three different protocols as follows: (i) Ttc was
co-applied with ACh (Figures 4A1,A4); (ii) Ttc was pre-applied
for 12 s before superfusion with ACh alone (Figures 4A2,A5);
and (iii) 12 s pre-application of Ttc followed by its co-application
with ACh (Figures 4A3,A6). The percentages of Ip and Iss
inhibition by Ttc differed, depending on the specific protocol
(Figures 4B1,B2). Thus, in oocytes clamped at −60mV, co-
application of Ttc and ACh blocked roughly half the control
Ip, as expected from its estimated IC50 (53 ± 3%, n = 20,
N = 9; Figure 4B1). However, the percentage of Issinhibition
increased to 74 ± 3% (same cells; p < 0.05, paired t-test;
Figure 4B1), mainly because of the acceleration of IACh decay
(compare black and red recordings of Figure 4A1). When Ttc
was solely pre-applied, before superfusion with ACh alone, the
percentage of Ip inhibition was significantly less (36 ± 2%;
n = 12, N = 4; p < 0.05, ANOVA; Figure 4B2) than when
Ttc and ACh were co-applied. No significant differences were
noted between the percentages of Ip and Issinhibition when
Ttc was solely pre-applied (Figure 4B1), indicating a very slow
recovery from this blockade. In contrast, Ttc pre-application,
followed by its co-application with ACh significantly increased
the percentage of Ip inhibition, as compared with their sole co-
application (67 ± 2% vs. 53 ± 3%; n = 15, N = 5; p < 0.05,
ANOVA and Bonferroni t-test; Figure 4B1). Furthermore, the
Iss blockade (79 ± 2%) was significantly greater than the
Ip inhibition (p < 0.05, paired t-test), indicating that IACh
decay was accelerated when Ttc was pre-applied, and later co-
applied with ACh. Indeed, the IACh decay time constants (see
below) observed when Ttc was co-applied with ACh alone,
and when Ttc was pre-applied and then co-applied with ACh
were similar (compare Figure 4A1 and Figure 4A3). It is also
interesting that the percentage of Ip remnant when Ttc was
first pre-applied, and then co-applied with ACh (33%) was
very close to the expected value if Ttc binding sites with
sole Ttc pre-application, and Ttc and ACh co-application (64
and 47% of control Ip, respectively) were independent (30%).
Thus, interactions of Ttc with resting and open nAChRs
agree with an allotopic model, as we previously observed for
DMA and DEA interactions on nAChRs (Alberola-Die et al.,
2016b).
When the membrane potential was held at +40mV,
the extent of IACh blockade by 0.7µM Ttc was smaller
than that at −60mV in any of the three above-mentioned
protocols (Figure 4A4-A6). Nevertheless, as observed at−60mV,
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FIGURE 3 | Pharmacological profile of nicotinic acetylcholine receptor (nAChR) blockade by tetracaine (Ttc). (A) IAChs evoked by different ACh concentrations (10,
100µM, and 1mM) either alone (A1,A2, black recordings), co-applied with 0.7µM Ttc (A1, red recordings), or co-applied with 0.7µM Ttc, after Ttc pre-application for
12 s at the same concentration (A2, red recordings). (B) Averaged ACh concentration-IAChamplitude relationship. IAChs were evoked by different ACh concentrations
alone (filled black circles; n = 10–13, N = 3), or co-applied with 0.7µM Ttc, either directly (open circles; n = 3–6, N = 2), or subsequent to its pre-application (open
triangles; n = 4–7, N = 2). Data were normalized to the maximal IACh elicited by ACh alone and fitted to the Hill equation (solid and dashed lines). (C) Percentage of
(Continued)
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 August 2018 | Volume 11 | Article 193
Cobo et al. Mechanisms of nAChR Inhibition by Tetracaine
FIGURE 3 | IACh inhibition when different ACh concentrations were directly co-applied with 0.7µM Ttc (circles and solid line; n = 9–33, N = 4–13), or after
pre-application of the same Ttc concentration for 12 s (triangles and dashed line; n = 11–21, N = 2–6). Asterisks indicate significant differences in the percentage of
IACh inhibition between ACh-Ttc co-application alone, and pre- and co-application of Ttc at each ACh concentration (p < 0.05, t-test). ACh concentration effected no
significant changes in the extent of inhibition by Ttc, either when Ttc and ACh were directly co-applied, or when this co-application was preceded by Ttc
pre-application (p > 0.05, ANOVA; except at 3µM ACh, indicated by the pound sign. However, IAChs at such low ACh concentration are too small for accurate
determination of the percentage of inhibition).
FIGURE 4 | Effect of tetracaine (Ttc) application timing and holding potential on nicotinic acetylcholine receptor (nAChR) blockade. (A) IAChs elicited at −60mV
(A1,A2,A3) and at +40mV (A4,A5,A6) by co-application of 10µM ACh and 0.7µM Ttc (Co-app; A1,A4), sole Ttc pre-application before superfusion of the agonist
(Pre-app; A2,A5), or Ttc pre-application followed by its co-application with ACh (Pre- and co-app; A3,A6). (B) Column graphs showing the percentages of IACh
inhibition by Ttc at −60mV (B1) and +40mV (B2) at the Ip (red filled columns) and the Iss (red striped columns), when Ttc was applied as indicated in (A). Asterisks
indicate significant differences between IACh inhibition by Ttc at Ip and Iss (p < 0.05, paired t-test). Pound signs indicate significant differences of Ip inhibition among
Ttc application-timing protocols, as compared with the values for ACh and Ttc co-application (p < 0.05, ANOVA and Bonferroni t-test). Note that IACh decay was only
accelerated (i.e., significant differences observed between Ip and Iss inhibition) when Ttc was either co-applied with ACh, or pre-applied and later co-applied with
ACh, at −60mV. Each column represents the average obtained from 12 to 20 oocytes (N = 4–9) for (B1), and from 6 to 11 cells (N = 2–3) for (B2).
the highest IACh inhibition was found with Ttc pre- and
co-application, and the lowest inhibition with just Ttc pre-
application (Figure 4B2). Interestingly, at +40mV, IACh decay
was not enhanced by Ttc when it was either just co-applied with
ACh or pre- and co-applied, in contrast to its effects observed
at −60mV. Therefore, at positive potentials the percentages
of Ip and Iss inhibition were similar in all tested protocols
(Figure 4B2).
In addition, we tested the effects of a 12 s pulse of 0.7µM
Ttc, applied during the Iss elicited by a 40 s pulse of 10µM ACh
(Figure 5A). This co-application of ACh and Ttc evoked a fast
and large inhibition of Iss (Iss reduced by 75 ± 2%; n = 13,
N = 4). Notably, the kinetics of this IACh blockade showed the
same temporal course as that observed for membrane currents
elicited by superfusion with a high-K+ solution. This indicates
that the timing of this Iss inhibition was only limited by the
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perfusion kinetics (see Figures 5B,C). In contrast, Iss recovery
after Ttc removal exhibited slower kinetics (time constants of
1.49 ± 0.09 s vs. 3.00 ± 0.23 s, for Ttc onset and recovery
phases, respectively; p < 0.05, t-test), which was not limited
by the solution exchange kinetics (compare with the high-
K+ solution washout; Figure 5C). Nevertheless, the kinetics
of IACh recovery when Ttc blocked open nAChRs was much
faster than that after the blockade of closed nAChRs (see
Figure 4A2).
Ttc Enhancement of nAChR
Desensitization
At concentrations of 0.5µM or higher, Ttc accelerated IACh
decay (see Figure 1). This acceleration might have originated
from one of the following two mechanisms (or a combination of
both): (i) a slow blocking effect of Ttc on nAChRs, which would
boost IACh decline after its peak; (ii) an enhancement of nAChR
desensitization. To discriminate between both possibilities, we
assessed the effect of 0.7µM Ttc on the IACh decay elicited
by two different concentrations of ACh (10 and 100µM),
because desensitization is markedly dependent on agonist
concentration. As previously reported, IACh decay followed a
two-exponential function (see Figures 6A1,A2), although the
slower component was too slow for accurate analysis using
this experimental approach (Morales and Sumikawa, 1992).
Thus, considering only the time constant (τ ) of the fast
component of IACh decay, it is clear that IACh declined at
a slower rate at 10µM ACh (Figure 6A1; τCtr = 15.6 ±
2.1 s, n = 12, N = 6) than at 100µM ACh (Figure 6A2;
τCtr = 5.9 ± 0.7 s, n = 18, N = 6; p < 0.05, t-test).
In the presence of 0.7µM Ttc, the IACh decay showed a
different trend in acceleration at 10µM (τTtc = 1.0 ± 0.1 s)
and at 100µM ACh (τTtc = 0.6. ± 0.1 s; p < 0.05, t-test;
Figures 6A1,A2). Thus, a constant Ttc dose had a more potent
effect on accelerating IACh decay when a higher concentration
of ACh was used. This finding rules out the notion that
the enhancement of IACh decay is merely due to a delayed
nAChR blockade, mediated by slow Ttc binding. Therefore,
the maximum percentage of change in IACh decay elicited by
0.7µM Ttc was achieved earlier, when it was co-applied with
100µM ACh (2.6 s) than with 10µM ACh (4.2 s; Figure 6B,
arrows). These results strongly suggest that Ttc enhances nAChR
desensitization.
Co-application of 10µM ACh with different concentrations
of Ttc (0.01–2µM) also highlights the fact that Ttc enhances
nAChR desensitization at concentrations close to, or above
its IC50. As shown in Figure 7, low Ttc concentrations
(0.01–0.1µM) elicited a significant IACh blockade (up
to 30%; Figures 7A1,C), but did not modify IACh decay
(Figures 7A2,B). In contrast, ACh co-applied with 0.7–
2µM Ttc significantly increased both the extent of nAChR
blockade (Figures 7A3,A5,C) and the rate of IACh decay
(Figures 7A4,A6,B). The lack of an acceleration of IACh decay
by low Ttc concentrations, which nonetheless reduced IACh
amplitude, presents evidence against the hypothesis of a slow
nAChR blockade by Ttc being responsible for a boost in IACh
FIGURE 5 | Effect of tetracaine (Ttc) application while nicotinic acetylcholine
receptors (nAChRs) were activated by 10µM acetylcholine (ACh). (A) Two
superimposed IAChs elicited by 40 s pulses of ACh. The red recording shows
the fast inhibitory effect of 0.7µM Ttc, superfused when indicated by the red
horizontal bar. The kinetics of IACh inhibition followed an exponential function
(green trace) with a time constant similar to those found for membrane
currents evoked by superfusion of a high-K+ (70mM) solution (blue recording
in B). Onset and decay of the K+ current were fitted to exponential functions
(discontinuous green line). (C) Time constant values of the exponential
functions fitted to the onset (On) and recovery (Off) of IACh blockade by Ttc
and K+ currents. Note that the rate of IACh inhibition is conditioned by the
solution exchange kinetics, but IACh recovery, after Ttc removal, exhibited
slower kinetics. Asterisk indicates significant differences (n = 13, p < 0.05,
ANOVA test).
decay, and supports the theory that Ttc indeed enhances nAChR
desensitization.
Further evidence indicating that Ttc promotes faster nAChR
desensitization arise from computation of the ratios of Iss vs.
Ip amplitudes, when co-applying 10µM ACh with different
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FIGURE 6 | Acceleration of IACh decay by tetracaine (Ttc) is dependent on the
concentration of acetylcholine (ACh). (A) Plot of averaged IACh decay
(expressed in percentages) elicited by 10µM ACh (A1; n = 12, N = 6) or
100µM ACh (A2; n = 18, N = 6), either alone (black recordings) or co-applied
with 0.7µM Ttc (red traces). Green lines over the averaged recordings
represent two-exponential functions fitted to the IACh decay. Insets are
representative recordings of IAChs elicited by 10µM ACh (A1) or 100µM ACh
(A2), either alone (black recordings), or co-applied with 0.7µM Ttc (red
traces). The Ip amplitudes in the presence of Ttc have been normalized to their
(Continued)
FIGURE 6 | control values for easier comparison of decay kinetics.
(B) Averaged percentages of change in IACh decay elicited by 0.7µM Ttc,
computed as the difference between IAChs obtained in the absence and
presence of Ttc, for currents evoked by 10µM ACh (green line; n = 12; N = 6)
or 100µM ACh (blue line; n = 18, N = 6). Notice the earlier maximum decay
acceleration (arrows) when IACh was evoked by 100µM ACh. Zero time
corresponds to the beginning of Ttc-ACh co-application and the downward
deflections are due to the earlier Ip in the presence of Ttc (see inset of A1).
concentrations of Ttc, as proposed by Sobolevsky et al. (1999)
(see Equation 2 in section Materials and Methods and Figure 8).
At low concentrations of Ttc (lower than 0.5µM), the quotient
of the Iss to Ip ratio in the presence of Ttc (Iss_Ttc/Ip_Ttc) over
the Iss to Ip ratio in the presence of ACh alone (Iss_Ctr/Ip_Ctr)
was close to 1. However, at higher Ttc concentrations (0.5µM
or above), this quotient was significantly smaller than 1
(p < 0.05; one-sample t-test), and interestingly, was reduced
in a dose-dependent manner, as the extent of Iss inhibition
by Ttc increased (Figure 8B). Therefore, the plot in Figure 8B
illustrates that low Ttc concentrations elicit nAChR blockade
without affecting IACh decay, whereas Ttc concentrations over
0.5µM evoke both (i) IACh reduction by nAChR blockade;
and (ii) acceleration of IACh decay by enhancement of nAChR
desensitization.
On the other hand, the kinetics of IACh tails (deactivation)
differed when ACh was withdrawn, but Ttc remained in
the ANR. In these experiments, 100µM ACh, which evokes
considerable nAChR desensitization, was co-applied with either
0.1 or 0.7µM Ttc for 32 s, and ACh was then washed out,
while keeping the cell superfused with Ttc for an additional
12 s. As previously shown, the effects of Ttc on IACh are
concentration-dependent. Thus, 0.1µM Ttc elicited both a
small IACh reduction, and a slight, but significant, enhancement
of IACh decay, mainly of the fast desensitization component
(Figures 9A1,A2). Thus, the ratio of IACh decay time constant
values obtained in the presence of 0.1µM Ttc vs. ACh alone
was significantly smaller than 1 (0.69 ± 0.07; n = 12,
N = 6; p < 0.05, one-sample t-test). Notably, co-application
of 10µM ACh together with 0.1µM Ttc did not modify
IACh decay (Figures 7A2,B), whereas the same concentration
of Ttc co-applied with 100µM ACh significantly accelerated
IACh decay (Figure 9A2). When 100µM ACh was co-applied
with 0.7µM Ttc, nAChR blockade was increased and IACh
decay was accelerated (Figures 9A1,A2). The ratio of IACh decay
time constant values obtained in the presence of 0.7µM Ttc
and ACh alone was 0.23 ± 0.08 (n = 13, N = 8). This
indicates that at this Ttc dose, the IACh decayed significantly
faster than in the presence of 0.1µM Ttc (p < 0.05, t-test).
Moreover, IACh deactivation after ACh withdrawal, followed a
single exponential time course, the kinetics of which was affected
by keeping Ttc in the ANR (Figures 9A3,A4). Deactivation of
control IAChs, elicited by ACh alone, followed an exponential
function with a time course that was limited by the solution
exchange kinetics (time constant of 1.4 ± 0.1 s, n = 25; see
Figure 5); thus, we would refer to these values as apparent
deactivation time constants (τapparent−deactivation). The presence
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FIGURE 7 | Acceleration of the decay of currents elicited by ACh (IACh) is dependent on the concentration of tetracaine (Ttc). (A) Representative IAChs elicited by
10µM ACh, either alone (black; A1-A6), or co-applied with 0.1µM (orange; A1), 0.7µM (red; A3), or 2µM Ttc (purple; A5). The same IAChs are in the right-hand
(A2,A4,A6), but their peak amplitudes were normalized to show more effectively the differences on IACh decay. (B) Normalized and averaged IACh decay elicited by
10µM ACh, either alone (black trace; n = 43, N = 12), or plus 0.01µM (brown trace; n = 12, N = 4); 0.1µM (orange trace; n = 9, N = 3); 0.7µM (red trace; n = 12,
N = 6); or 2µM Ttc (purple trace; n = 10, N = 4). Each averaged IACh decay was fitted by a two-exponential function (green lines overlapping each recording). Note
that with Ttc concentrations of up to 0.1µM, the IACh decay overlaps the control. (C) Percentages of IACh inhibition by 0.01, 0.1, 0.7, and 2µM Ttc (same cells and
color codes as in B) at different times after Ip. Low Ttc concentrations blocked nAChRs, but they did not modify IACh decay. In addition, note that the time-dependent
increase in the percentage of IACh inhibition was already established 2 s after Ip. For each Ttc concentration, asterisks indicate significant differences among the
percentages of IACh inhibition at different times, as compared with their respective Ip (p < 0.05, ANOVA, Bonferroni t-test).
of Ttc decelerated IACh deactivation in a dose-dependent manner
(τapparent−deactivation of 1.9 ± 0.3 and 2.9 ± 0.3 s for IAChs in the
presence of 0.1 and 0.7µM Ttc, respectively; same cells as above;
Figures 9A3,A4,B), as ACh washout kinetics remained constant.
Deceleration of IACh deactivation would be expected if Ttc
enhances nAChR desensitization, as has been previously reported
for GABAARs (Jones and Westbrook, 1995). Accordingly, a
linear correlation exists between the extent of desensitization (see
Equation 2 in section Materials and Methods) and the apparent
deactivation time constant values in the presence or absence of
Ttc (Figure 9B).
Virtual Docking Assays
The interactions between Ttc and the nAChR were explored by
using the full structure of Torpedo nAChRs as a template in both
the open and closed conformations (Alberola-Die et al., 2016a,b).
For each conformation we carried out 800 runs to assess Ttc-
nAChR interactions. We found 279 clusters of interaction sites
differing by less than 5 Å of the root-mean-square-deviation for
the nAChR in the open state and 257 in the closed state. As
shown in Figure S3 (open state) and Figure S4 (closed state),
these clusters were located at the ECD (87 and 89% for open
and closed states, respectively) and at the TMD (13 and 11% for
open and closed states, respectively). No clusters were found at
the intracellular domain (ICD). Most nAChR-Ttc interactions at
the ECD involved two subunits (53 and 57% for open and closed
states, respectively), mainly α1-γ, α2-δ, close to the orthosteric
binding site, and α1-β for both the open and closed states
(Figures S3Cc1, S4Cc1). In contrast, TMD clusters were involved
in simultaneous binding to residues of 3–5 subunits deep within
the channel pore (Figures S3Cc2, S4Cc2). In addition, there were
TMD clusters located close to the ECD-TMD interface, at intra-
or inter-subunit crevices, comprising 1 or 2 subunits, respectively
(Figures S3Cc3,c4, S4Cc3,c4). Notably, Ttc was bound to roughly
the same nAChR residues within the channel pore in both open
and closed states (see Table 1). Conversely, less overlapping was
observed with respect to Ttc binding to residues at the ECD
and inter- and intra-subunit crevices of the TMD. Thus, only
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FIGURE 8 | IACh desensitization increases with increasing tetracaine (Ttc)
concentration. (A) IAChs evoked by 10µM ACh, either alone (black; A1,A2) or
co-applied with 0.1µM (orange recording; A1), or 0.7µM Ttc (red trace; A2).
Ip and Iss values are indicated by arrows in the IAChs elicited solely by ACh
(Ip_Ctr and Iss_Ctr ), or together with Ttc (Ip_Ttc and Iss_Ttc). Note that Ip_Ttc
(Continued)
FIGURE 8 | was reached earlier than Ip_Ctr . (B) Relationship between changes
in IACh desensitization (see Equation 2) and extent of Iss inhibition evoked by
different concentrations of Ttc (0.01–2µM). The black discontinuous line is a
reference indicating no change in desensitization and the blue line is the best
linear fit to values falling below the reference line (0.1–2µM Ttc). Each point
represents the average obtained from 7 to 19 oocytes (N = 2–9), except for
0.5µM Ttc, in which n = 3 and N = 1. Asterisks indicate significant differences
from control desensitization (p < 0.05, one-sample t-test).
22 out of 47 (46.8%) residues that were bound to Ttc at the
ECD in the closed state were also bound to this LA in the
open state (Table 1). A similar percentage of coincidence was
found when considering intra- and inter-subunit residues of the
TMD, specifically 16 out of 26 (61.5%) and 14 out of 33 (42.4%),
respectively (Table 1).
Given the strong effect of Ttc on IACh decay elicited by
the enhancement of nAChR desensitization, and the presence
of this effect only at negative potentials (see Figure 4), it is
logical to consider that Ttc increases desensitization through
its binding within the channel pore. To assess this hypothesis,
we performed additional docking assays focused just at the
channel pore when it was in the open conformation. Further,
150 runs were performed to assess Ttc-nAChR channel pore
interactions and docking developed at the same residues located
at the middle of the channel pore, in a similar manner
to those reported above, using the whole nAChR structure
(Figure S3Cc2, and Figure 10Aa1). In an attempt to explore
further Ttc-nAChR interactions in the channel, we blocked
Ttc binding at the residues indicated above. Additional runs
carried out under the specified conditions showed that Ttc
also binds, although with a lower affinity, to residues of α1,
α2 (E262 and L263), and γ subunits (N224, L267, Q270,
K271, and E274), located at the channel pore, close to the
extracellular side (Figures 10Aa2,B;Table 1). Interestingly, when
this approach was repeated using the nAChR in the closed
conformation, we found that Ttc was bound to coincident
sites within the channel pore, despite the fact that the sole
pre-application of Ttc did not affect the rate of IACh decay
(Figure 4A2).
Table 2 reflects the theoretical binding energy and Kd values
(Equation 4) of Ttc docking solutions at the three main nAChR
binding sites both in the resting and open states: site-1, the ECD;
site-2, the outer mouth of the pore; and site-3, located deeper
within the channel pore (see image of Table 2). In the resting
state, the binding energy of site 2, which corresponds to the
low-affinity site, was lower than those of either sites 1 (ECD)
or 3 (the high-affinity site within the pore). Similarly, in the
open state, the Ttc binding energy of site 2 was significantly
lower than those observed for sites 1 and 3 (p < 0.05, t-test).
In contrast, the ECD sites presented similar Kd values, both
in the open and resting states, and they were comparable to
those of site 3 in the closed state. Additional binding energy
data with details of interfaces and locations are depicted in
Table S1.
When the present manuscript was under review, Newcombe
et al. (2018) published a refined structural model of the nicotinic
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FIGURE 9 | Deactivation kinetics of currents elicited by ACh (IACh) are dependent on the concentration of tetracaine (Ttc). (A) Representative IAChs elicited by 100µM
ACh, either alone (black recording), or together with 0.1µM (orange) or 0.7µM (red) Ttc (A1). Superfusion of Ttc lasted 12 s after ACh washout. These recordings
were normalized to the same Ip (A2) to show changes in desensitization more effectively. (A3) Deactivation of IAChs shown in (A1). The black arrow indicates ACh
washout and the red arrow indicates Ttc removal. (A4) IACh deactivations shown in (A3) were scaled to the same amplitude to better compare their time course.
(B) Relationship between desensitization changes (Equation 2) and the apparent deactivation time constant (τapparent−deactivation) elicited by 0.1µM (orange triangle)
and 0.7µM (red circle) Ttc. The black filled symbol corresponds to the τapparent−deactivation of IAChs elicited by ACh alone, which is rate limited by the solution
exchange kinetics. The green discontinuous line indicates the control desensitization ratio. Note the higher desensitization rate elicited by Ttc (values lower than 1 in
the ordinate), and the slower deactivation rate (higher τapparent−deactivation values in the abscissa) following a linear relationship (blue discontinuous line). Each point
represents the average of 12–25 oocytes from eight donors. Asterisks indicate significant differences in desensitization and deactivation (p < 0.05, t-test), with respect
to control values and the pound means differences in both parameters depending on the Ttc concentration used (p < 0.05, t-test).
α7 subunit. This model corrects a previously identified error
in the TMD alignment of Torpedo subunits, which mainly
involves a shift of one helix turn at the base of the M1-M2
helices. As a refined model for the different subunits forming
the muscle-type nAChR is not available, we used the structure
of homomeric α7 nAChRs, in both the open and closed states, to
assess the relevance of the M1-M2 loop and nearby M2 residues
in Ttc binding. After conducting 800 docking runs in each
conformation, we found no Ttc interactions on the M1-M2 loop
or nearby residues of the M2 helix (see Figure S5). Therefore, the
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TABLE 1 | Nicotinic acetylcholine receptor (nAChR) residues interacting with tetracaine (Ttc) in open and resting (closed) states.
Receptor state Domain (location) Interfaces Subunits Residues
Open EC α-γ αγ W149, T150, Y151, D152, Y190, P197, Y198
γ R78, Y116, L118, P120
α-δ αδ W149, T150, Y151, D152, P197, Y198
δ S40, N55, W57
α-β αγ T106, K107, L108, L109, M117, W118, T119, P120
β Y149, T150, Y151, D152
TM (M2) αγ/αδ S248, L251, S252, V255, F256, E262, L263
β S254, L257, A258, V261, F262
δ C262, L265, A266, V269, F270
γ N224, S256, L259, A260, I263, F264, L267, Q270, K271, E274
TM (intersubunit) β-δ β F219, Y220, V222, Y223
δ L287, I288, G289, L292, M296
α-γ αδ F214, N217, V218, I220, P221, L224
γ T262, L265, F266, A269, P273
TM (intrasubunit) αγ/αδ I264, L273, Y277, M278, F280, T281, F284
β K269, V270, S274, P278, I279, I280, I281, Y283
δ K224, Y228, F232, I233, L278, L287, Y291, F294, I295
γ L219, I222, I225, I226, Y285, F288, V289, T468
Resting EC α-γ αγ V91, L92, Y93, A96, I148, W149, T150, D152, Y198
γ W54, R78, L108, Y116, L118
α-δ αδ V91, L92, Y93, N95, A96, I148, W149, Y198
δ S40, N41, N55, W57, V104, P123, I125
α-β αγ R55, T106, K107, L108, L109, W118, T119, P120, P121
β V91, L92, N96, G98, S99, F100, Y149, T150, Y151
TM (M2) αγ/αδ S248, L251, S252, V255, F256, E262
β S254, L257, A258, V261, F262
δ C262, L265, A266, V269, F270
γ N224, S256, L259, A260, I263, F264, K271
TM (intersubunit) β-δ β P217, L218, F219, Y220, I221, V222, Y223
δ L278, P279, A282, L283, V285, P286, L287, L292
α-γ αδ N217, I220, P221, L224, F225, L228, L253, F256, I260
γ T262, L265, F266, I268, A269, M290, S293, L294, V297
TM (intrasubunit) αγ/αδ L273, Y277, M278, F280, T281, F284
β V270, S274, V277, P278, I279, I280, I281, Y283
δ Y291, F294, L298, G301, V302, N305
γ I268, F288, V289, V292, S293, I296
Main nAChR residues at extracellular (EC) or transmembrane (TM) domains, where Ttc binds when the receptor is in the open or the resting state. Red labeled residues are located at
a shallow depth within the channel pore and seem to be involved in enhancement of the desensitizing effects of Ttc. Coincident interacting residues in both nAChR configurations are
indicated in bold font in the resting state.
M1-M2 loop and nearby residues do not appear to be relevant
targets of Ttc, at least in the homomeric nAChR. In addition,
the inaccuracies of the original Torpedo structural model do
not seem to substantially affect the docking results presented
above.
DISCUSSION
This work confirms that Ttc is a powerful blocker of muscle-type
nAChRs and deepens our understanding of the modulatory
mechanisms of LAs associated with nAChR function. Along
with other LAs that possess tertiary amine groups, such as
lidocaine, Ttc shares some similar effects on nAChRs. However,
there are also significant differences among their effects. For
instance, the potency of Ttc as a nAChR blocker (IC50 of 0.3
and 0.7µM, for the Iss and Ip, respectively) is comparable
to that of d-tubocurarine, and markedly higher than those of
lidocaine (11–73µM) (Gentry and Lukas, 2001; Alberola-Die
et al., 2011) or procaine (25–230µM) (Adams, 1977; Koblin
and Lester, 1979; Gentry and Lukas, 2001; Wang et al., 2010).
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FIGURE 10 | Idealization of two putative tetracaine (Ttc) binding sites within the channel pore. (A) Lateral (upper) and top (lower) views of the transmembrane domain
(TMD), in the open nicotinic acetylcholine receptor (nAChR), showing Ttc (highlighted in cyan) bound at the higher affinity (at the middle of the pore; a1) and lower
affinity (closer to the extracellular side; a2) sites. (B) Lateral view of the three nAChR domains (membrane bilayer in gray). The two Ttc binding loci within the channel
pore are highlighted by a square. A zoomed in image of this frame, from the synaptic cleft, is shown on the right. Ttc molecules (in purple) were used to block the
high-affinity site within the pore, to reveal the Ttc low-affinity binding site (Ttc interacting molecules shown in brown), which includes E262(α), N224(γ), K271(γ), and
E274(γ) as key interacting residues.
Notably, the Ttc IC50 here reported is roughly one order
of magnitude smaller than the value found for muscle-type
nAChRs expressed in a human cell line (TE671/RD; 13µM)
(Gentry and Lukas, 2001) and roughly one hundredth the IC50
reported for mouse cells (BC3H-1; 38µM) (Eterovic´ et al., 1993).
Nevertheless, our Ttc IC50 was similar to the value stated for
nAChRs from the electric organ of Torpedo californica expressed
in Xenopus oocytes (1µM) (Eterovic´ et al., 1993), but smaller
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TABLE 2 | Binding energies and dissociation constants (Kd) of tetracaine (Ttc) bound to closed and open muscle-type nicotinic acetylcholine receptors (nAChRs).
Receptor state Binding site location Mean binding energy (kcal/mol) (n) K d (M)
Resting 1 4.79 ± 0.54 133 3.08 × 10−4
2 3.67 ± 0.67* 12 2.05 × 10−3
3 4.75 ± 0.19 66 3.31 × 10−4
Open 1 4.53 ± 0.66 107 4.74 × 10−4
2 3.48 ± 0.36* 33 2.79 × 10−3
3 3.94 ± 0.51# 58 1.28 × 10−3
The main Ttc binding sites are denoted as (1) at the extracellular domain (ECD); (2) at the low-affinity site within the pore; and (3) at the high-affinity site within the pore. See right-hand
figure for their location within the nAChR. Different binding energies of the same locations were averaged to get a single energy value, which is indicated together with its standard
deviation. The Kds were calculated using Equation 4 (see section Materials and Methods). Asterisks indicate significant differences between Ttc binding energies of site 2 and those of
either sites 1 or 3, in both the open and closed conformations (p < 0.05, t-test); the pound sign denotes significant differences between sites 1 and 3 in the open state; n is the number
of docking solutions that were averaged.
than that obtained for nAChRs from Electrophorus electricus
electroplaques (25µM) (Koblin and Lester, 1979). The large
differences in the blocking potency of Ttc among nAChRs from
the electric organ and muscle-type nAChRs expressed in diverse
cells lines could be due to the different subunit conformations
of these receptors; specifically, the synaptic-type (ε-like subunit)
composition of the former and the extrasynaptic-type (γ-like
subunit) composition of the latter. Nevertheless, whether or not
muscle-type nAChRs from fetal (or denervated muscle) and
adult muscles have the same sensitivity to Ttc remains to be
assessed.
The main effect of Ttc on nAChRs at low concentrations,
below its IC50, was a voltage-dependent blockade
(Figures 2A1,B1), indicating that Ttc enters the channel
pore. This blockade resembles that elicited by other LAs and
compounds with tertiary amine groups, such as lidocaine
(Alberola-Die et al., 2011), procaine (Adams, 1977), and
DEA (Alberola-Die et al., 2016a). The kinetics of the voltage-
dependent blockade was assessed by stepping back the cell
membrane potential from +40mV (which ejects Ttc from its
binding site within the channel) to −60mV, while the cell was
superfused with 10µM ACh and Ttc. At 0.1µM, Ttc most
likely binds only to the high-affinity site (site 3) within the
channel, and the elicited voltage-dependent blockade could be
fitted by a single exponential function. Notably, at 0.7µM Ttc
(a concentration at which Ttc might bind to sites 2 and 3), the
blocking kinetics also followed a single exponential function,
but with a faster time constant, as would be expected with an
increase in the number of blocking molecules. Therefore, these
results suggest that most of the voltage-dependent blockade
by Ttc is due to its binding to site 3. In accordance with
these findings, the slope of the voltage-dependent blockade at
negative potentials remains essentially unaltered at different
concentrations of Ttc (see Figure S2). It should be noted
that the voltage-dependent blockade of nAChRs by charged
molecules is intermittent, with very fast kinetics, causing the
characteristic current “flickering” (Neher and Steinbach, 1978).
In contrast, it is likely that the effect on desensitization is a
more long-lasting phenomenon, as it involves conformational
changes. Thus, it is possible that Ttc binding to site 2 mainly
promotes nAChR desensitization, leading to non-conducting
desensitized nAChR, instead of a plain open-channel blockade,
which is more easily reversible. At high concentrations (IC50
or above), Ttc also elicited a voltage-independent blockade of
nAChRs (Figures 2A2,B2). This additional nAChR blockade is
most likely due to the action of Ttc on nAChR residues located
outside the channel pore, as it was also present at positive
potentials, which should have removed most of the positively
charged Ttc from the pore. Nevertheless, according to the
Woodhull model (Woodhull, 1973), some IACh inhibition could
be observed at positive potentials when using relatively high
blocker concentrations, if the blocker binds at a shallow site
within the channel pore, as Ttc does (see the mild slope of the
voltage-dependent blockade of IACh in Figure S2). Even so,
the charged cholinesterase inhibitor BW284c51, which elicits
open-channel blockade of Torpedo nAChRs through its binding
to a shallow site within the channel (delta of 0.1; i.e., very
close to the extracellular side) (Olivera-Bravo et al., 2007) does
not inhibit IACh at positive potentials, when tested at its IC50
(Olivera-Bravo et al., 2005, 2007). Moreover, the hypothesis of a
single Ttc binding site cannot explain several key experimental
results reported in the present study, such as: (i) the marked
differences between Ttc unbinding kinetics when Ttc is just
pre-applied (either at −60 or +40mV; Figure 4A2,A5) and
when it is applied during the IACh (Figure 5); (ii) the higher
nAChR blockade evoked by 0.7µM Ttc when it is pre-applied
and then co-applied with ACh, as compared to the effect of just
Ttc and ACh co-application (Figures 4B1,B2); (iii) the changes
in IACh decay, found solely when ACh was co-applied with
Ttc at concentrations close to, or above, the IC50 (Figure 7B);
(iv) the slower IACh deactivation in the presence of Ttc, and
its correlation with the acceleration of IACh decay (Figure 9B),
which strongly suggests that both are due to the enhancement
of nAChR desensitization; (v) the lack of acceleration in IACh
decay by Ttc when holding the membrane potential at positive
potentials (compare recordings Figure 4A1 and Figure 4A4);
and (vi) the different nAChR-Ttc interaction sites found in our
docking assays, associated with both the ECD and TMD (see
inset of Table 2 and Figures S3, S4). All these experimental data
provide strong evidence (although not irrefutable proof) that the
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effects of Ttc on IACh are mediated by its binding to multiple sites
in the nAChR.
As indicated above, Ttc increased its inhibitory effect
when pre-applied to the cell, before its co-application
with ACh (Figure 3B,C), suggesting a resting-channel
blockade. Indeed, Ttc binding to closed nAChRs has been
previously reported, either by measuring the inhibition of
labeled perhydrohistrionicotoxin binding to nAChR-enriched
membrane fragments (Blanchard et al., 1979; Middleton
et al., 1999) or by photolabeling nAChR-rich membranes with
radioactive Ttc (Gallagher and Cohen, 1999; Middleton et al.,
1999). These authors found a Ttc binding affinity roughly
30-fold higher in the resting state than in the desensitized
state (IC50s of ≈ 1µM vs. 30µM, respectively; Blanchard
et al., 1979; Middleton et al., 1999), and reported that Ttc
binds within the channel pore while the nAChR is in the
closed state (Gallagher and Cohen, 1999). Accordingly, our
docking assays on nAChRs showed that Ttc binds within the
channel pore, both in the open and closed conformations
(site 3 of Table 2; Figures S3A,Cc2, S4A,Cc2, respectively),
and become involved with the same residues in both states
(see Table 1). Notably, the M2 residues interacting with Ttc at
the middle of the channel pore are roughly the same as those
reported for Ttc interactions with resting nAChRs (Gallagher
and Cohen, 1999). Although our in silico results do not show
that M2 residues had a higher Ttc binding affinity when the
nAChR was in the open state, the selective open-channel
blockade elicited by low concentrations of Ttc indicate that
these residues should have had the highest affinity for Ttc.
Nevertheless, the docking data revealed that the Ttc binding
energies of site 3 were significantly higher than those of site
2 (located at a shallower depth in the TMD; see Table 2) and
roughly similar to those of site 1 (binding sites at the ECD).
Our virtual docking assays on the resting nAChR showed
that Ttc interacts mostly with residues located at the ECD
(Figure S4). Furthermore, the functional results suggest that
Ttc binds to different (independent) sites, whether the nAChR
is closed or open (Figure 4), and this binding is dependent
on the concentration of Ttc administered. In this regard, it
should be pointed out that the concentration of Ttc used for
the photolabeling experiments was 5µM (Gallagher and Cohen,
1999), which is almost one order of magnitude higher than
our IC50 value, and roughly 50-fold the concentration of Ttc
that elicits selective voltage-dependent blockade of nAChRs
(Figures 2A1,B1).
As would be expected from the above-mentioned open-
and closed-channel blockade, the pharmacological profile of
nAChR inhibition by Ttc followed a non-competitive pattern
(Figure 3B). Therefore, the extent of IACh inhibition was
independent of agonist concentration (Figure 3C), although
it was affected by the timing of Ttc application (direct co-
application ACh and Ttc vs. pre-application of Ttc, followed by
its co-application with ACh). Interestingly, when 0.7µM Ttc
was pre-applied alone, the IACh inhibition elicited either at −60
or +40mV, showed almost no recovery during the following
32 s pulse of ACh (Figures 4A2,A5,B1,B2). We could speculate
that Ttc partition in the membrane would account for this slow
IACh recovery. Indeed, protonated Ttc, similar to other molecules
with charged ammonium groups, could interact with negatively-
charged phosphate groups of membrane phospholipids through
long-range coulombic interactions (Pérez-Isidoro et al., 2014).
However, membrane adsorption of Ttc at the concentrations
used in the present study (below 1µM) does not seem to
sufficiently explain the delayed and long-lasting nAChR blockade
found with just pre-application of Ttc. Instead, we think
that the sustained nAChR blockade when Ttc was solely pre-
applied would be due to Ttc binding outside the channel
pore in resting nAChRs (closed-channel blockade), as it was
found at both negative and positive potentials (Figures 4A2,A5).
Accordingly, Figure 5 shows that Ttc “off” rate kinetics of
IACh (roughly 3 s; Figure 5C) is only moderately slower than
its corresponding “on” rate (time constant values circa 1.5 s),
but much faster than the IACh recovery observed after Ttc
pre-application alone. Furthermore, quaternary ammonium
molecules, such as BW284c51 or edrophonium, show similar
washout kinetics (in the range of a few seconds) (Olivera-
Bravo et al., 2007), even if they are superfused at very
different concentrations (0.5µM and 10µM for BW284c51 and
edrophonium, respectively). Furthermore, Leng et al. (2013)
reported the Ttc inhibition of ASIC3 channels by repeating,
within the same cell, pH pulses with increasing concentrations
of Ttc, up to 30mM. Despite the high Ttc doses used in that
study (over four orders of magnitude above those used in
the present study to block nAChRs), no additive effects were
apparent when pulses were repeated at 90 s intervals. All of
these experimental findings contradict the possibility that the
membrane acts as a large reservoir for lipid-partitioned Ttc
molecules, which would slowly release Ttc after being washed
out from the solution, and thus, sustain nAChR inhibition over
time.
When Ttc dose-nAChR inhibition curves were plotted for
both Ip and Iss values (Figure 1C), they showed that Ttc
inhibition was rather similar for both components up to
0.1µM Ttc. However, at higher concentrations of Ttc, there was
increased inhibition at the Iss. This increase in IACh blockade at its
steady state is directly related to the enhancement of IACh decay,
which requires the action of Ttc within the channel pore. Thus,
it was not observed when the cell membrane was maintained
at positive potentials, which eject the positively charged Ttc
from the channel pore (compare recordings of Figures 4A1,A4).
The acceleration of IACh decay by Ttc might be mediated
by either a slow-pace blockade of nAChRs, enhancement of
desensitization, or a combination of both factors. However,
we have assembled several experimental findings that support
the hypothesis that the main reason is an increase in the rate
of nAChR desensitization. First, the same Ttc concentration
(0.7µM) accelerated IACh decay more sharply when it was co-
applied with 100µM ACh (τTtc = 0.6 s) than with 10µM ACh
(τTtc = 1.0 s) (Figure 6). Second, as already mentioned, Ttc at its
IC50 blocked nAChRs at both negative and positive potentials,
but IACh decay was only enhanced when the cell was maintained
at negative potentials (Figures 4A1,A4). Third, the Ttc blocking
kinetics was faster than the acceleration of IACh decay induced
by Ttc. Thus, the time course of the voltage-dependent blockade
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of nAChR by 0.7µM Ttc was faster (Figure 2C) than the
IACh decay evoked by the same concentration of Ttc, even
when co-applied with a high concentration of ACh (100µM;
τTtc = 0.6 s, Figure 6). Fourth, if Ttc would accelerate IACh
decay because of a slow-pace blockade of nAChRs, it should
be detected at all concentrations of Ttc that induce IACh
inhibition. However, 0.1µM Ttc, which inhibits roughly 25%
IACh (Figures 1, 7), does not modify IACh decay (Figure 7).
Fifth, at Ttc concentrations above 0.5µM, the ratio Iss/Ip vs.
its corresponding control value (in the presence of 10µM ACh
alone) is significantly smaller than 1 (Figure 8B), indicating
an enhancement of nAChR desensitization (Sobolevsky et al.,
1999). In contrast, below 0.5µM Ttc, this quotient is close to 1
(Figure 8B). Sixth, Ttc decelerated IACh deactivation (Figure 9).
The pronounced deceleration of IACh deactivation elicited by
Ttc, when applied at its IC50, also indicates an enhancement
of nAChR desensitization, because of the higher affinity of
the desensitized nAChR to the agonist, as previously suggested
for GABAARs (Jones and Westbrook, 1995). Nevertheless, the
solution exchange kinetics of our experimental model limits the
temporal resolution to roughly 1.4 s (Figure 5). Therefore, to
assess the kinetics of the voltage-dependent IACh blockade, the
cell membrane potential was jumped from positive to negative
voltages in the presence of Ttc, which facilitated themeasurement
of this kinetics independently of the solution exchange rate
(Figure 2). However, as IACh deactivation kinetics is affected
by the solution exchange rate, we referred to the observed
values as apparent deactivation time constants, to indicate this
limitation.
Altogether, the aforementioned results indicate that Ttc
indeed enhances nAChR desensitization. Furthermore, both our
functional and virtual docking results support the notion that
Ttc accelerates nAChR desensitization by binding to M2 residues
located at the interphase between the ECD and TMD (site 2 of
Table 2), a region that is relevant to the determination of both
the open-channel lifetime and rate of desensitization of Cys-
loop receptors (Bouzat et al., 2008). Thus, our functional studies
indicate that Ttc requires binding within the channel to boost
desensitization, as IACh decay is not affected by Ttc at positive
membrane potentials, which eject Ttc from the channel lumen.
Consistent with these findings, our docking assays indicated that
Ttc binds to residues of the α and γ subunits located at a very
shallow depth within the channel pore (Figures 10Aa2,B and
Tables 1, 2), both in the open and closed states. Interestingly, one
of these residues is αE262, which is located at the extracellular
end of the channel pore. This residue is highly conserved
among different nAChRs subtypes and has been involved in
the desensitization/resensitization of Torpedo nAChRs (Forman
et al., 2007). Indeed, αE262 mutants have the fast component
of nAChR desensitization altered, and photomodification of
αE262 with 3-azioctanol stabilizes the desensitized state (Forman
et al., 2007). In addition, crystal violet, a nAChR antagonist,
reportedly enhances the desensitization of resting receptors,
likely by binding to αE262, and stabilizes the desensitized state
(Arias et al., 2006). Notably, Ttc inhibits crystal violet binding
to resting AChRs (Arias et al., 2006), suggesting that both
molecules interact at the same, or nearby sites. However, in our
hands, Ttc did not promote changes in desensitization when
acting on resting nAChR, as the IACh decay was not accelerated
by the sole pre-application of Ttc, i.e., when Ttc acted on
resting receptors only. Moreover, if Ttc had desensitized resting
nAChRs, a slow increase of the IACh would be expected during
the subsequent ACh application, because of the slow recovery
of nAChR from desensitization; however, no changes in IACh
decay were observed with this protocol (Figure 4A2). In contrast,
Ttc binding to site 2 enhances nAChR desensitization when
the channel is in the open conformation, as evidenced by the
accelerated IACh decay observed when Ttc and ACh were co-
applied, either directly, or following a 12 s pre-application of
Ttc (Figures 4A1,A3). Interestingly, this superficial binding site
in the channel pore differs from another, more deeply located
within the channel (site 3), to which Ttc binds with higher
affinity, thereby eliciting open-channel blockade (steric blockade;
Figure 10). Nevertheless, our docking assays used the structural
models ofTorpedo nAChR derived from cryo-eletronmicroscopy
as a template, which bears a rather low resolution, particularly
in the open-channel model (6.2 Å) (Unwin, 1995). Moreover,
these templates contain an error in the TMD alignment that
is mainly associated with a shift of one helix turn at the base
of the M1-M2 helices. Nevertheless, this TMD region does not
appear to be a target of Ttc, neither when the original Torpedo
templates were used, nor when the homomeric α7 nAChR refined
structure was used (Newcombe et al., 2018). This suggests that
the inaccuracies of the original Torpedo structural model do
not substantially affect the docking results presented. Thus,
our virtual docking assays provide a coherent explanation of
our experimental observations, in terms of the involvement of
different sets of Ttc binding sites that account for its complex
modulating actions on nAChRs.
In conclusion, our present results indicate that Ttc, a molecule
that is widely used in clinical practice for both topical and
spinal administration, should no longer be considered only as
a non-competitive blocker of nAChRs that selectively act on
the resting (closed) state (Middleton et al., 1999). Here, we
provide strong functional evidence indicating that Ttc is a very
powerful blocker of muscle-type nAChRs, with an IC50 in the
submicromolar range, which acts on both the closed and open
states of nAChRs. Furthermore, Ttc greatly enhances nAChR
desensitization, most likely by binding to the most superficial
region of the pore when the channel is in the open conformation.
It is worth noting that as around 100µM Ttc is required to
inhibit 80% of voltage-dependent Na+ channels (Wang et al.,
1996), the high potency of Ttc inhibiting muscle-type nAChRs,
and perhaps other neuronal subtypes of nAChRs, might explain
some of its serious side effects, despite the fact that it is rapidly
hydrolyzed by plasma esterases (Moriya, 2005). Nevertheless, Ttc
concentrations in plasma of up to 0.7µM have been reported in
humans after its topical application on the skin (2 g, 5% w/w),
without any remarkable side effects (Mazumdar et al., 1991).
Although roughly all Ttc molecules in physiological solutions
are protonated, in contrast to other LAs with amine groups,
Ttc binds to different nAChR loci, which accounts for the
heterogeneity of its functional effects on nAChRs. These results
contribute to a better understanding of the complex modulation
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of muscle-type nAChRs by Ttc, and they provide new insights
about the key nAChR loci involved in both allosteric and steric
modulation.
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